Table 1 Patient Characteristics (n = 875)
Age at diagnosis, median (range), years | 56 (30–90) | ||
Follow-up time, median (range), months | 29 (1–115) | ||
Menopausal status | Postmenopausal | 602 | 68.8 % |
Premenopausal | 273 | 31.2 % | |
Vital status | Died | 345 | 39.4 % |
Alive | 448 | 51.2 % | |
Censored | 82 | 9.4 % | |
Family history | Yes | 230 | 26.3 % |
No | 643 | 73.7 % | |
CA125 level | <500 U/ml | 193 | 22.6 % |
≥500 U/ml | 662 | 77.4 % | |
Ascites | No | 99 | 11.3 % |
<500 ml | 146 | 16.7 % | |
≥500 ml | 629 | 72.0 % | |
FIGO Stage | Early (I, II) | 75 | 8.6 % |
Advanced (III, IV) | 800 | 91.4 % | |
Cytoreduction | R0 | 272 | 31.1 % |
R1 | 434 | 49.6 % | |
R2 | 169 | 19.3 % | |
Chemosensitivity | Yes | 568 | 66.9 % |
No | 237 | 27.9 % | |
NA | 44 | 5.2 % | |
Platelet count (median, IQR)(×109/L) | 301 (235–383) | ||
Thrombocytosis | Yes | 121 | 13.8 % |
No | 753 | 86.2 % | |
Fibrinogen level (median, IQR)(g/L) | 3.85 (3.19–4.45) | ||
Hyperfibrinogenemia | Yes | 332 | 45.9 % |
No | 392 | 54.1 % | |